Article

Sotrovimab drives SARS-CoV-2 Omicron variant evolution in immunocompromised patients

2022-04-16

Abstract excerpt

After monoclonal antibody sotrovimab implementation, Rockett et al have warned on March 9th about two resistant mutations in the spike at position 337 and 340 occurring within the first week in four immunocompromised patients infected by a Delta variant and resulting in viable infection up to 25 days. As sotrovimab is currently the only effective treatment against BA.1 lineage of Omicron variant, we investigated t...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 590bea2b-cc77-5b81-aa66-6b920ed01d44
DOI: 10.1101/2022.04.08.22273513

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Sotrovimab drives SARS-CoV-2 Omicron variant evolution in immunocompromised patientsDOI 10.1101/2022.04.08.22273513Read

Sotrovimab drives SARS-CoV-2 omicron variant evolution in immunocompromised patientsSemantic proximity Read

Frequent emergence of resistance mutations following complex intra-host genomic dynamics in SARS-CoV-2 patients receiving SotrovimabSemantic proximity Read

Frequent Emergence of Resistance Mutations Following Complex Intra-Host Genomic Dynamics in SARS-CoV-2 Patients Receiving Sotrovimab.Semantic proximity Read

High incidence of sotrovimab resistance and viral persistence after treatment of immunocompromised patients infected with the SARS-CoV-2 Omicron variantSemantic proximity Read

Longitudinal Analysis of Escape Mutations in SARS-CoV-2 Omicron Variants after Sotrovimab Use in Immunodeficient PatientsSemantic proximity Read

Sotrovimab: A Review of Its Efficacy against SARS-CoV-2 VariantsSemantic proximity Read

Emergence of Delta and Omicron variants carrying resistance-associated mutations in immunocompromised patients undergoing sotrovimab treatment with long-term viral excretion.Semantic proximity Read

Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 and BA.5 subvariant predominance: a systematic literature reviewSemantic proximity Read

A Systematic Review on the Emergence of Omicron Variant and Recent Advancement in TherapiesSemantic proximity Read

In-Silico Analysis of Monoclonal Antibodies against SARS-CoV-2 Omicron.Semantic proximity Read

Complex intra-host SARS-CoV-2 evolution following monoclonal antibody pre-exposure prophylaxisSemantic proximity Read

Potential Benefit of Early Treatment with Sotrovimab in Patients With High Risk for Severe COVID-19 Carrying BA.2 InfectionSemantic proximity Read